« Such deep molecular responses, to our knowledge, have never been seen in patients with myelofibrosis before,” Kiladjian noted »
»A previously developed mathematical model for predicting long-term responses in patients with PV and ET was found to be applicable to this study and predicted a long-term decrease and potential eradication of hematopoietic stem cells »
Ruxolitinib approved for myelofibrosis in 2 categories
Good article on Pacritinib
Myelofibrosis - thank you for the support 
Myelofibrosis patient experience talk -I'd like to do one at the Oxford Forum on 24th April
